TP53 and myelodysplastic syndrome: To complicate matters, it is well established that TP53-mutated MDS is fairly chemo-resistant [40,67,68], with infrequent and short-lived responses to HMA therapy even when combined with venetoclax, making it increasingly challenging to clear TP53 mutations before allo-HCT.